Grant Pickering, MBA

Chief Executive Officer, Director and Founder

Grant has nearly 30 years of experience in the pharmaceutical and biotech arena having responsibility for multiple vaccines and immunotherapeutic drug approvals and the formation and financing of multiple successful platform companies. Prior to starting Vaxcyte, Mr. Pickering was the CEO of Mymetics Corporation, a public European-based vaccine company developing a prophylactic RSV vaccine, based on a virosomal platform technology. Prior to that, he was an executive-in-residence at Kleiner, Perkins, Caufield & Byers, while serving as the CEO at Juvaris BioTherapeutics, whose immunotherapeutic and vaccine adjuvant platform yielded multiple animal health products launched by its alliance partner Bayer HealthCare, including Zelnate® and Victrio®. Prior to Juvaris, Mr. Pickering spent many years at Dendreon Corporation where he played a prominent role in the company’s IPO and led clinical development, operations and business development culminating in the launch of the therapeutic prostate cancer vaccine, Provenge®. He also led marketing and business development for the pain management platform company, Algos Pharmaceutical Corporation, which was acquired by Endo Pharmaceuticals. Mr. Pickering began his career at Glaxo and Johnson & Johnson in sales, marketing, and clinical research roles culminating in the launches of Flonase® and Floxin®. Mr. Pickering earned his BS degree in marketing from The Pennsylvania State University and his MBA from Georgetown University with high honors. Outside of Vaxcyte, Grant enjoys spending time with his wife and kids, living vicariously through their soccer triumphs, and gives back through mentoring and supporting education both domestically and in developing countries. Grant’s loyalty to his hometown of Kansas City was finally doubly rewarded as both the Royals and the Chiefs were crowned world champions since Vaxcyte got rolling.

Jim Wassil, MS, MBA

Chief Operating Officer

Jim brings extensive experience in the development and commercialization of vaccines having spent the past three decades in positions of increasing responsibility in the vaccine divisions of Merck, Novartis, and Pfizer. He was responsible for the development and launch of Menveo, the meningococcal conjugate vaccine, as well as Bexsero, and the ABCWY vaccine candidate while at Novartis Vaccines. Most recently he worked at Pfizer, Inc as the business unit lead for Pfizer Vaccines, where he was responsible for market access, policy, pricing, tender negotiations, epidemiology and health outcomes for the full vaccine portfolio, including the pneumococcal conjugate vaccine franchise (Prevnar 13). Previously he led international marketing for the pediatric vaccine franchise at Merck Vaccines where he launched RotaTeq®, a vaccine for rotavirus gastroenteritis in infants and children, and held other technical and operational roles of increasing responsibility within research, manufacturing, quality, regulatory, and technology transfer. Mr. Wassil earned a Bachelor of Science degree in chemistry/biology with high honors from the University of Notre Dame and a master of science degree in bio-organic chemistry and a master of business administration degree, both from Lehigh University.  In 2014, James received the VIVA Award as Novartis’ top scientist in 2014 for development and approval of Bexsero®.  He also was an ACE Finalist (Secretary of State Award for Corporate Excellence) for his role in conducting an effectiveness study of RotaTeq in Nicaragua.

Jeff Fairman, Ph.D.

Vice President of Research and Founder

Jeff has over 20 years of experience in the biotech arena having led the research at multiple platform companies that he co-founded resulting in multiple clinical candidates and approved vaccines and immunotherapeutics. Prior to Vaxcyte, Jeff was the founder and Vice President of Research at Juvaris BioTherapeutics, whose immunotherapeutic & vaccine adjuvant platform yielded multiple animal health products launched by its alliance partner Bayer HealthCare, including Zelnate® and Victrio®. While at Juvaris, Jeff was the recipient of major grant funding from multiple sources, including NIH and NCI, supporting substantial pre-clinical programs and multiple clinical studies. He was responsible for research activities resulting in multiple clinical candidates and the approved animal health products. Prior to Juvaris, Jeff was the Director of Pharmacogenomics at Clingenix and Senior Scientist at Valentis. Dr. Fairman has a Ph.D. in Chemistry and his postdoctoral training was in the genetics of leukemia at MD Anderson Cancer Center. Jeff enjoys spending time with his wife and daughter and has put his amateur taekwondo career on hold, for the time being, to be courtside rooting for his daughter’s school and club volleyball teams.

Andrew Guggenhime, MBA

President and Chief Financial Officer

Andrew has more than 25 years of experience in finance and corporate development. Prior to joining Vaxcyte, Andrew served as Chief Financial Officer of Dermira, Inc. from April 2014 through the acquisition of the company by Eli Lilly and Company in February 2020. During his time at Dermira, Mr. Guggenhime executed on a wide range of financial and strategic transactions, including the company’s initial public offering, follow-on offerings and the sale of the company; planned and executed the transition to a commercial-stage organization in connection the company’s first product launch; and built and led business planning and process initiatives for multiple corporate functions. Prior to Dermira, Andrew served as Chief Financial Officer for CardioDx, Inc., a privately held commercial-stage molecular diagnostics life sciences company. He also served as Chief Financial Officer for Calistoga Pharmaceuticals, Inc., a privately held, development-stage company, which was acquired by Gilead Sciences, Inc. in 2011; and as Chief Financial Officer for Facet Biotech Corporation, a biotechnology company that was acquired by Abbott Laboratories in April 2010. He previously served as Chief Financial Officer of PDL BioPharma, Inc. until Facet Biotech was spun off from PDL BioPharma in December 2008. Prior to joining Facet Biotech, Mr. Guggenhime served as Chief Financial Officer for Neoforma, Inc. a provider of supply chain management solutions for the healthcare industry, which was acquired by Global Healthcare Exchange, LLC in March 2006. Mr. Guggenhime began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He currently serves on the board of directors of Metacrine, Inc., a privately held biotechnology company. Mr. Guggenhime holds an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.A. in international politics and economics from Middlebury College. Andrew enjoys spending quality family time and traveling with his wife and three children, skiing, tennis and golf and, as a native San Franciscan, watching his hometown Giants, 49ers and Warriors.

Paul W Sauer, MBA

Senior Vice President, Process Development and Manufacturing

Paul has over 30 years of experience industrializing biologics for numerous biotechnology companies. Prior to joining Vaxcyte, Paul was VP of Process Sciences & Manufacturing at Igenica Biotherapeutics, where he initiated the company’s development activities and built its supply chain network for GMP manufacturing of its antibody drug conjugates. Prior to that, Paul was Senior Director of Process Development at OncoMed Pharmaceuticals, where he contributed to multiple IND filings for the company’s antibody-based oncology therapies. He also held various process, engineering, scale-up, and manufacturing positions at Protein Design Labs, Scios, and Genentech. Through the years, Paul has contributed to numerous approved biologics, including Genentech’s Activase® and Pulmozyme®. He also contributed significantly to the development of the patented high-yield process that formed the basis for production of Abbvie and Biogen’s ZinbrytaTM, a humanized antibody approved for the treatment of Multiple Sclerosis. Paul earned an MBA at Santa Clara University and a BS in Genetics from the University of California, Davis. Paul enjoys spending quality time with his family and helping his wife with her non-profit organization focused on transforming health through diet.

Harp Dhaliwal

Senior Vice President, Commercial Manufacturing and Supply Chain

Mr. Dhaliwal has 25 years of experience in engineering, operations strategy, manufacturing and supply chain, with significant expertise in the healthcare industry. During his career, he has led commercial manufacturing and supply chain for multiple products. Most recently, Mr. Dhaliwal served as Senior Vice President of Supply Chain, Manufacturing and Procurement at Dermira and transitioned to Eli Lilly following the company’s acquisition. In this role, he supported Dermira’s first product launch and successfully transitioned the cGMP manufacturing network from clinical to commercial. Previously, Mr. Dhaliwal was the Head of Manufacturing and Supply Chain at Medivation, an oncology-focused company. Following Pfizer’s acquisition of Medivation, Mr. Dhaliwal led the operations integration. Previously, Mr. Dhaliwal had a long career at Biogen where he ultimately served as Biogen’s Chief Procurement Officer, responsible for managing $3 billion of enterprise-wide spend. While at Biogen, he was also instrumental in transforming the manufacturing network, initiating the biosimilar business and other strategic initiatives.

Mr. Dhaliwal has an MBA in Science and Technology from Queen’s University and a Bachelor of Chemical Engineering from the University of British Columbia. Harp’s free often involves golfing with his three young daughters, long walks with his wife on the beach, home projects and occasional game nights with the family.